Interpace Diagnostics Announces Expanded Coverage Among Blue Cross Blue Shield Plans
14 New Plans Cover ThyGenX® and ThyraMIR® in 2018 to Date
PARSIPPANY, N.J., May 10, 2018 -- (Healthcare Sales & Marketing Network) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (Interpace or the Company), a fully integrated commercial a... Diagnostics, Oncology, Reimbursement Interpace Diagnostics, ThyraMir, thyroid cancer, PancraGEN, pancreatic cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Marketing | Pancreas | Pancreatic Cancer | Pharmaceuticals | Thyroid | Thyroid Cancer